The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Eli Lilly partners with ABL Biotech on bispecific antibodies via the Grabody platform in a deal worth up to $2.6B. Read more ...

Eli Lilly’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s ...

Eli Lilly and Company (NYSE: LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Eli Lilly receives CDSCO approval for donanemab, a new Alzheimer's treatment targeting early symptomatic stages of the ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.